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Abstract
We report the construction of a cell-based fluorescent reporter for anthrax lethal factor (LF) 
protease activity using the principle of fluorescence resonance energy transfer (FRET). This was 
accomplished by engineering an Escherichia coli cell line to express a genetically encoded 
FRET reporter and LF protease. Both proteins were encoded in two different expression 
plasmids under the control of different tightly controlled inducible promoters. The FRET-based 
reporter was designed to contain a LF recognition sequence flanked by the FRET pair formed by 
CyPet and YPet fluorescent proteins. The length of the linker between both fluorescent proteins 
was optimized using a flexible peptide linker containing several Gly-Gly-Ser repeats. Our results 
indicate that this FRET-based LF reporter was readily expressed in E. coli cells showing high 
levels of FRET in vivo in the absence of LF. The FRET signal, however, decreased 5 times after 
inducing LF expression in the same cell. These results suggest that this cell-based LF FRET 
reporter may be used to screen genetically encoded libraries in vivo against LF.
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Introduction
The exposure of U.S. postal workers to Bacillus anthracis, the pathogen causing anthrax, 
in 2001 revealed a gap in the nation’s overall preparedness against bioterrorism.
B. anthracis infections are difficult to treat because flu-like symptoms appear only after 
the bacteria have multiplied inside the human host and started to produce the corresponding 
bacterial toxin that eventually causes death. If classical antibiotics are applied at this stage, the 
infection can be still lethal because of the accumulation of the corresponding bacterial toxin. A 
pharmacological agent that directly targets the toxin might thus prove to have a valuable synergy 
with more traditional antibacterial treatments.
The high pathogenicity of anthrax is mostly due to rapid bacterial growth combined with 
the secretion of three powerful exotoxin components: edema factor (EF), lethal factor (LF), and 
protective antigen (PA). EF is a calcium and calmodulin-dependent adenylate cyclase (AC) that 
converts cellular ATP into cyclic AMP (cAMP) [1]. LF is a Zn2+-dependent metalloprotease [2]
that cleaves and inactivates mitogen-activated protein kinase kinases (MAPKKs) [3]. PA binds 
to a cell surface anthrax toxin receptor (ATR/TEM-8 or CMG-2) [4; 5; 6] where it is activated by 
proteolytic cleavage by furin-like proteases [7]. This step enables the formation of an heptameric 
pore [8] that allows cellular entry of LF and EF. Once inside the cell, LF and EF cause extensive 
cellular damage to the host cell defense system. Although the complete mechanism of 
pathogenesis is not yet fully understood, the disruption of key signaling pathways mediated by 
MAPKKs seems to lead first to the lysis of macrophages [9; 10], impairment of dendritic cells 
and later to the death of the host [11]. The pivotal role of LF in the virulence of the toxin 
suggests that inhibitors of this enzyme may provide protection against cytotoxicity. 
The first step in the design of potential inhibitors is the development of a rapid, sensitive, 
and simple assay for testing a large number of compounds, usually referred as libraries [12; 13; 
14]. Classical methods for LF assays, such as HPLC [15] and SDS-PAGE [16; 17], are 
impractical for high-throughput screening of compound libraries, either of chemical or biological 
origin. The development of new fluorescence-based substrates, however, has opened the door for 
high-throughput screening of LF inhibitors [18; 19; 20]. Optimized synthetic peptides containing 
various types of fluorophores have been reported for fast, sensitive, and robust assays suited for 
high-throughput screening [13; 21].
In recent years, the introduction of green fluorescent protein (GFP) to fluorescence 
resonance emission transfer (FRET)-based activity assays has introduced a new avenue to study 
proteases and their inhibitors inside living cells [22; 23]. The recent design of fluorescent 
proteins optimized for FRET [24] has enabled for the first time the use of new high-throughput 
screening applications using sensitive fluorescence-activated cell sorting (FACS) [24; 25]. 
The combination of FACS with FRET-based genetically encoded proteolytic reporters 
allows the possibility for in vivo screening of protease inhibitors using chemically generated [12; 
13] or biologically encoded libraries [14]. The later possibility suggests an even more intriguing 
scenario in which single cells can be used as individual microfactories for the biosynthesis and 
screening of particular inhibitors in a single process within the same cellular cytoplasm [26]. 
This strategy also has the advantage in that the screening process takes place in a complex 
molecular environment, which provides the ideal background for the selection of highly specific 
inhibitors.
Recent developments in the fields of molecular biology and protein engineering have 
now made possible the in vivo biosynthesis of cyclic peptide–based combinatorial libraries [27; 
28; 29; 30; 31; 32] that can be screened in vivo against LF. Interestingly, several natural 
products, including defensin peptides [33; 34] and aminoglycosides [35], have been recently 
shown to inactivate LF factor.
Key to the idea of using genetically encoded cell libraries for the in vivo screening of 
potential inhibitors against LF using FACS is the development of a robust cell-based fluorescent 
assay for LF. In the present work, we report an Escherichia coli cell line that has been 
engineered to express both LF protease and a FRET-based LF substrate under the control of two 
orthogonal and inducible bacterial promoters. The FRET-based LF substrate was designed to 
contain a consensus LF recognition sequence [36] flanked by a FRET pair of optimized 
fluorescent proteins, a cyan fluorescent protein (CyPet) and yellow fluorescent protein (YPet) 
[24]. Several tandem CyPet–YPet fusion proteins with different linkers were generated and 
evaluated in vitro for maximum substrate accessibility, while maintaining high FRET efficiency. 
The fluorescent LF reporter was readily expressed in E. coli showing high levels of FRET in vivo
in the absence of LF. Conversely, the FRET signal was significantly reduced when LF and its 
FRET-based substrate were sequentially expressed in the same cell line. Our results demonstrate 
that this cell-based FRET reporter for LF can be used to screen in vivo for LF inhibitors.
Materials and methods
General materials and methods. Analytical HPLC was performed on an HP1100 series 
instrument with 220-nm and 280-nm detection using a Vydac C18 column (5 µm, 4.6 x 150 mm) 
at a flow rate of 1 mL/min. Semipreparative HPLC was performed on a Waters Delta Prep 
system fitted with a Waters 2487 Ultraviolet-Visible (UV-vis) detector using a Vydac C18 
column (15–20 µm, 10 x 250 mm) at a flow rate of 5 mL/min. All runs used linear gradients of 
0.1% aqueous trifluoroacetic acid (TFA, solvent A) vs. 0.1% TFA, 90% acetonitrile in H2O 
(solvent B). UV-vis spectroscopy was carried out on an Agilent 8453 diode array 
spectrophotometer, and fluorescence analysis was performed on a Spex FluoroLog-3 
spectrofluorometer (Jobin Yvon). Electrospray mass spectrometry (ES-MS) analysis was 
routinely applied to all protein constructs. ES-MS was performed on an MDS Sciex API-150EX 
single quadrupole electrospray mass spectrometer. Calculated masses were obtained by using 
ProMac v1.5.3.  Protein samples were analyzed by SDS-PAGE on 4–20% Tris-Glycine Gels 
(Invitrogen). SDS-PAGE gels were stained with Pierce Gelcode Blue or Silversnap II stain kits, 
photographed/digitized using a Kodak EDAS 290, and quantified using NIH Image-J software 
(http://rsb.info.nih.gov/ij/). DNA sequencing was performed at Davis Sequencing facility (Davis, 
CA) using an ABI 3730 DNA sequencer. The sequence data were analyzed with Lasergene 
v5.5.2 (DNAStar). All chemicals were obtained from Sigma-Aldrich unless otherwise indicated.
Solid-phase peptide synthesis of the LF consensus peptide (H-RRKKVYPYPMEGTIA-
OH). Peptide synthesis was manually performed using the HBTU activation protocol for Fmoc 
solid-phase peptide synthesis [37] on a 4-Fmoc-Rink amide resin (Novabiochem). Coupling 
yields were monitored by the quantitative ninhydrin determination of residual free amine [38]. 
Protected Na-Fmoc amino acids were purchased from Novabiochem. Side-chain protection was 
employed as previously described for the Fmoc protocol. Methionine was introduced as 
unprotected Fmoc-Met-OH.
Construction of CyPet–YPet fusion protein reporters (1 to 6). The CyPet–YPet parent 
bacterial expression construct containing both optimized CyPet and YPet [24] was engineered as 
follows. First, DNA encoding CyPet was obtained by PCR amplification using the pCyPet-His 
plasmid [24] as a template. The DNA amplicon was then inserted into the NheI and BamHI sites 
of the T7 expression vector pET28a(+) (Novagen) to give plasmid pET28a-CyPet. In a second 
step, DNA encoding YPet was produced by PCR amplification using the pYPet-His plasmid [24]
as a template. This DNA was inserted in frame into the HindIII and XhoI sites of pET28a-CyPet 
to give plasmid pET28a-CyPet-YPet. The forward and reverse primers employed for the PCR 
amplification of the DNA encoding for CyPet are 5’-GGC CAG GAG TGC TAG CAT GTC 
TAA AGG TG-3’ and 5’-GGT GGT GGT GGG ATC CTT TGT ACA ATT CAT CC-3’, 
respectively. The forward and reverse primers employed for PCR amplification of the DNA 
encoding for YPet are 5’-CAC TAA GGC CAG GAA AGC TTC GAT GTC TAA AGG-3’ and 
5’-CCT TAG TGG TGG TGC TCG AGT TAT TTG TAC AAT-3’, respectively. In all the cases, 
the resulting PCR amplicons and plasmids were digested with their respective restriction 
endonucleases (NEB) and purified by gel using the QIAquick Gel Extraction Kit (Qiagen) prior 
to ligation with T4 DNA ligase (NEB). The DNA encoding the LF substrate consensus sequence 
[36] was cloned into the plasmid pET28a-CyPet-YPet using the BamHI and HindIII sites. 
Different inserts encoding the LF substrate flanked by various repeats of the flexible tripeptide 
GGS were prepared (Figure 1). Constructs 1, 2, 3, 4, and 5 encoded 0, 1, 2, 4, and 6 pairs of the 
tripeptide GGS, respectively, and were prepared as follows. 5’-Phosphorylated top (p5) and 
bottom (p3) strand oligonucleotides were synthesized by IDT DNA (Coralville, IA) (Table 1). 
Complementary strands were annealed in 20 mM sodium phosphate, 0.3 M NaCl buffer at pH 
7.4 and the resulting double-stranded DNA (dsDNA) was purified using QIAquick PCR 
Purification Kit (Qiagen). In plasmids encoding constructs 4 and 5, the dsDNA inserts were 
constructed by first ligating the dsDNA resulting from annealing oligonucleotides p5a-p3a and 
p5b-p3b (see Table 1). The resulting dsDNA was 5’-phosphorylated with T4 PNK (NEB). This 
strategy was employed due to the decreased yield and purity associated with synthetic 
oligonucleotides larger than 100 bases. All the dsDNA inserts were introduced in frame into the 
BamHI and XhoIII sites of pET28a-CyPet-Ypet to give plasmids pET28a-1 to pET28a-5.
Reporter protein construct 6 is similar to construct 5 but it was cloned into the expression 
vector pBAD/Myc-HisA (Invitrogen) using the SacI and KpnI restriction sites to give plasmid 
pBAD-6. Forward and reverse primers containing SacI and KpnI, respectively, were used to 
amplify by PCR the DNA encoding construct 5 using pET28a-5 as a template. The resulting 
amplicon was inserted into the SacI and KpnI sites of the expression vector pBAD/Myc-HisA. 
The forward and reverse primer sequences used in the PCR amplification are 5’-ATA TAT GAG 
CTC TAG CAT GTC TAA AGG TGA AGA-3’ and 5’-AAT ATA GGT ACC TTG TAC AAT 
TCA TTC ATA CCC-3’, respectively. 
All plasmids were first transformed into competent E. coli DH5a cells (Invitrogen) and 
plated on Luria broth (LB)-agar containing either kanamycin (34 mg/L) for the pET28a-derived 
vectors or ampicillin (100 mg/L) for the pBAD-derived vector. Positive colonies were grown in 
5 mL of LB containing the appropriate antibiotic at 37°C overnight and the corresponding 
plasmid purified using a miniprep kit (Qiagen). Plasmids were either screened by PCR using the 
same cloning primers or by digestion using the same restriction endonucleases used for cloning. 
Positive plasmids were sequenced and screened for bacterial expression.
Expression and purification of CyPet–YPet fusion protein reporters (1 to 5). E. coli
Rosetta 2(DE3) cells (Novagen) were transformed with plasmids pET28a-1 to pET28a-5. 
Expression was carried out in 1 L of LB medium containing ampicillin (100 mg/L) and 
chloramphenicol (34 mg/L) at 20°C overnight. Briefly, 5 mL of an overnight starter culture 
derived from a single clone was used to inoculate 1 L of LB media. Cells were grown to an OD 
at 600 nm of ≈ 0.5 at 37°C, and expression was induced by the addition of isopropyl-b-D-
thiogalactosidase (IPTG) to a final concentration of 0.25 mM at 20°C overnight. The cells were 
harvested by centrifugation, resuspended in 30 mL of lysis buffer (0.1 mM PMSF, 25 mM 
sodium phosphate, 150 mM NaCl buffer at pH 8.0 containing 5% glycerol) and lysed by 
sonication. The lysate was clarified by centrifugation at 15,000 rpm in a Sorval SS-34 rotor for 
30 minutes. The clarified supernatant was incubated with 1 mL of Ni-NTA agarose beads 
(Qiagen) previously equilibrated with column buffer (25 mM sodium phosphate, 150 mM NaCl 
buffer at pH 8.0) at 4°C for 1 hour with gentle rocking. The Ni-NTA agarose beads were washed 
sequentially with column buffer containing 10 mM imidazole (100 mL) followed by column 
buffer containing 20 mM imidazole (100 mL). The fusion protein was eluted with 2 mL of 
column buffer containing 100 mM EDTA. Proteins were characterized as the desired product by 
ES-MS (see Figure 1). Quantification of the CyPet–YPet fusion proteins was carried out 
spectrophotometrically using an extinction coefficient per chain at 517 nm of 104,000 M-1cm-1
[22; 24]. Approximately 10 mg of FRET reporter protein were purified per 1 L of culture grown 
as indicated above.
Construction of LF protease expression vector (pRSF-LF). The DNA encoding LF protease from 
B. anthracis strain Sterne was isolated by PCR using the pTXB1-LF plasmid [20] as a template. 
The forward (5’-TAA GGA TCC GGC GGG CGG TCA TGG TGA-3’) and reverse (5’-GCA 
TCT CCC GTG ATG CAG GAA-3’) primers contained a BamHI and NotI restriction site, 
respectively. The resulting amplicon was purified using Qiagen’s PCR purification kit, digested 
and ligated into BamHI- and NotI-treated plasmid pRSFDuet-1 (Novagen) to give T7 expression 
vector pRSF-LF. The resulting plasmid was sequenced and shown to be free of mutations.
Expression and purification of LF protease. E. coli BL21(DE3) cells (1L) transformed with 
pRSF-LF plasmid were grown to mid-log phase (OD600 ≈ 0.5) in LB medium containing 
kanamycin (34 mg/L) and induced with 0.15 mM IPTG at 22°C for 16 hours. The cells were 
pelleted by centrifugation, resuspended in 30 mL of lysis buffer and lysed by sonication. The 
lysate was clarified by centrifugation and purified on Ni-NTA agarose beads as described above. 
The protein was eluted with column buffer containing 100 mM EDTA and dialyzed against LF 
reaction buffer (10 µM CaCl2, 100 µM ZnCl2, 10 mM MgCl2, 20 mM NaPi, 100 NaCl buffer at 
pH 7.2). The purified protein was quantified by UV spectroscopy using an extinction coefficient 
per chain at 280 nm of 79,650 M-1cm-1, and characterized by SDS-PAGE and ES-MS (calculated 
molecular weight: 92949.0 Da, observed mass: 92980 ± 20 Da). The enzymatic activity of the LF 
protease was tested against the consensus peptide and the different FRET reporter constructs.
In vitro LF proteolytic assay using HPLC. An HPLC-based LF proteolytic assay was performed 
by incubating the consensus peptide (200 µM) with LF (10 µM) in 500 µL of LF reaction buffer 
at 37°C for 30 minutes and analyzed by HPLC and ES-MS. 
In-vitro FRET-based LF proteolytic assay. The enzymatic assay was performed by incubating 
the different FRET reporter constructs (1 to 5, 10 nM) with purified LF protease (10 nM) in 3 
mL of LF reaction buffer in a quartz cuvette. The reaction was kept with gentle stirring at 37°C 
for up to 180 minutes. Reaction progress was continuously monitored by fluorimetry using a 
Spex FluoroLog-3 spectrofluorometer with both excitation and emission slits set at 5 nm. For 
FRET measurements, the excitation wavelength was set to 414 nm and fluorescence scans were 
carried out at a rate of 2 nm/s from 450 nm to 600 nm. The relative FRET ratio change was 
calculated as previously reported [24] using: FRC = [(It525 / It475) / (I0525 / I0475)], where I0 and It
are the fluorescence intensities at time zero and at particular time (t), respectively, either at 525 
nm or 475 nm. 
Sequential expression of FRET reporter 6 and LF protease. E. coli BL21(DE3) cells were 
transformed sequentially with plasmid pBAD-6 and pRSF-LF. The resulting cells were grown at 
37°C to mid-log phase (OD600 ≈ 0.5) in LB media containing ampicillin (100 mg/L) and 
kanamycin (34 mg/L), and supplemented with 0.5 % glucose. Expression of FRET-based protein 
reporter 6 was induced by adding 1/100th culture volume of 20% w/v of L-arabinose for 8 hours 
at 30°C. During this period, an aliquot of L-arabinose was added every 4 hours. After the 
induction period, cells were incubated at 22°C overnight and then pelleted by centrifugation. The 
cells were washed once and then resuspended in minimal media M9 containing glycerol (4 
mL/L) as the sole carbon source, then supplemented with ampicillin (100 mg/L) and kanamycin 
(34 mg/L). Prior to the induction with IPTG, a 10 mL sample of cells was taken for fluorescence 
analysis. The rest of the cells were induced with 0.25 mM IPTG at 30°C. Small aliquots of cells 
were taken at different time points for fluorescence analysis.
In vivo FRET-based analysis of LF protease activity. Cell aliquots (1 mL) were briefly 
centrifuged at 5,000 rpm for 30 seconds, washed three times with 1 mL of PBS (20 mM NaPi, 
100 mM NaCl buffer at pH 7.2), and resuspended in 1 mL of PBS. The concentration of cells 
was finally adjusted to an OD600 of 0.6 with PBS. Cell samples (100 µL) were mixed with 2.9 
mL of PBS in a quartz cuvette kept at 37°C. The samples were gently stirred with a magnetic stir 
bar. Fluorescence analysis was performed as described in the in vitro experiments (see above). 
Protein concentrations were quantified by fluorescence using excitation and emission 
wavelengths of 490 nm and 525 nm, respectively, and then compared against the 525nm 
emission of purified FRET reporter of a known concentration previously calculated by UV-vis.
Results and Discussion
Molecular design, expression, and purification of FRET-based reporters for LF protease 
activity
The different LF FRET reporters (1 to 5) were constructed by fusing two optimized 
fluorescent proteins (CyPet and YPet) [24] to a consensus LF recognition sequence [36] (Figure 
1). The CyPet–Ypet pair was originally obtained by evolutionary optimization from cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP) by Daugherty and co-workers 
[24]. This optimized FRET pair enables intracellular FRET measurements with enhanced 
sensitivity and dynamic range, and thus allows the use of standard flow cytometry 
instrumentation for high-throughput analysis and screening applications [39]. This is critical for 
performing screening assays inside living cells. The LF consensus sequence was derived from a 
peptide obtained by Cantley and co-workers [36] from the analysis of partially degenerated 
peptide libraries to provide an optimal substrate for LF protease. This peptide incorporates 
consensus residues (P5-P4’) surrounding the scissile bond based on the peptide library screen, 
flanked by residues from MAPKK2. The crystal structure of this peptide with an inactive form of 
LF showed that nine residues of the substrate (from P3 to P6’) bind in an extended conformation 
along the 40 Å–long substrate recognition groove [36; 40]. Thus, in order to release any potential 
steric hindrance introduced by the two flanking fluorescent proteins on the peptide substrate, we 
designed several FRET-based reporters (1 to 5) encoding several repeats of the flexible tripeptide 
Gly-Gly-Ser [41] between the LF substrate and the CyPet and YPet fluorescent proteins (Figure 
1). 
Characterization of all the genetically encoded FRET-based reporters was carried out first 
in vitro. For this purpose, constructs 1 to 5 were first cloned onto a T7-driven bacterial 
expression vector, expressed in E coli and readily purified using Ni-NTA affinity 
chromatography. All the FRET reporters showed high expression levels (≈ 10 mg of pure protein 
per liter of culture), and were characterized by ES-MS and SDS-PAGE (Figures 1 and 2). 
Fluorescence properties of FRET-based reporters 1 to 5
Protein constructs 1 to 5 were analyzed by fluorescence spectroscopy to evaluate their 
FRET efficiency in the “on” state. In all the cases, CyPet–YPet fusion proteins showed high 
FRET values when excited at 414 nm. The FRET values, estimated as the ratio between the 
fluorescence intensities at 525 nm (maximum emission for YPet) and 475 nm (maximum 
emission for CyPet), ranged from 9.5 for construct 5 to 6.2 for construct 6 (see Figure 1). In 
contrast, an equimolar solution of YPet and CyPet gave a FRET value of only 0.7. As expected, 
increasing the length of the flexible linker (Gly-Gly-Ser)n decreased the FRET efficiency of the 
corresponding reporter proteins around 35% (construct 1 versus 6). It is interesting to note, 
however, the relatively high FRET values observed for constructs 4 and 5. These constructs 
contain 8 and 12 Gly-Gly-Ser repeats, which in a completely extended conformation have 
lengths of 78 Å and 116 Å, respectively. These values are well beyond the Foster radius (≈50 Å) 
assigned for the FRET pair formed by cyan and yellow fluorescent proteins [41]. Recent studies 
by Merkx and co-workers [41; 42] on the effect of flexible linkers in FRET-based biosensors 
have shown similar results, indicating that the behavior of these flexible linkers can be better 
described as random coils using either a worm-like chain or Gaussian chain model rather than as 
a totally extended conformation.
Expression and enzymatic activity of recombinant LF protease
The LF protease employed in this work was cloned from B. anthracis strain Sterne [20]
into a T7-driven pRSF bacterial expression plasmid [43]. The protein was readily expressed in E. 
coli and purified by Ni-NTA chromatography. A total of 10 mg of purified LF protease per liter 
of E. coli culture was routinely obtained. The activity of recombinantly expressed LF protease 
was tested using consensus peptide H-RRKKVYPYPMEGTIA-NH2 as a substrate in a 200:1 
peptide-to-enzyme ratio. The cleavage reaction was monitored by analytical RP-HPLC 
indicating that the protease was totally active. LF was able to cleave specifically the peptide 
bond between P1-P1’ residues of the peptide substrate in less than 15 minutes (data not shown) 
using the conditions described under Materials and Methods.
In vitro cleavage of FRET-based reporters 1 to 5 by LF protease
LF cleavage of FRET reporters 1 to 5 was monitored by fluorescence spectroscopy. This 
was carried out by treating a 10 nM solution of the corresponding FRET reporter with different 
amounts of purified LF protease at 37°C in LF reaction buffer. Under these conditions, all 
constructs showed between a 9- to 14-fold decrease in FRET signal upon cleavage with LF 
(Figure 3). Cleavage reactions were also monitored by SDS-PAGE (Figure 3B) confirming that 
the proteolytic cleavage was specifically taking place at the linker located between the two 
fluorescent proteins. As the cleavage reaction progressed, the initial band ≈57 kDa corresponding 
to the FRET reporter disappeared giving rise to a doublet of bands around 28 kDa. The FRET 
value once the cleavage was complete was estimated to be ≈ 0.7 in all the constructs. This value 
is similar to that found for an equimolar mixture of CyPet and YPet proteins.
We also explored the effect of the linker length on the efficiency of LF protease cleavage. 
As expected, the cleavage reaction proceeds more efficiently as the length of the flexible linker 
Gly-Gly-Ser increases. As shown if Figure 3C, the change in half-life time is more pronounced 
when we compare constructs 1 to 3. In each case, cleavage occurs about twice as fast with each 
pair of Gly-Gly-Ser repeats added, with t1/2 values of 33, 17, and 9 minutes, respectively. 
Constructs 3 to 6, however, showed very similar half-life times under the same reaction 
conditions, showing only a marginal increase in the rate of cleavage (t1/2 values for constructs 3, 
4, and 5 were 10, 9, and 8 minutes, respectively). These results confirm that the presence of two 
Gly-Gly-Ser repeats on each side of the LF recognition sequence is enough to release most of the 
steric hindrance introduced by the presence of the two large fluorescent proteins.
The cleavage of the FRET-based reporter by LF was also shown to be dose-dependent on 
the concentration of LF thus indicating that the cleavage was specific for the consensus sequence 
embedded in the FRET-based reporter protein. As shown in Figure 3D, the initial rate of 
cleavage for construct 3 was shown to be proportional to the concentration of LF used in a range 
from 10 to 100 nM. These results show the potential of these constructs to be used as a sensitive 
LF probe able to detect nM concentrations of LF protease in vitro.
Design of an LF protease FRET reporter system in live E. coli cells
Our next step was to explore the possibility of using a FRET-based reporter to work 
inside living E. coli cells for the in vivo screening of LF inhibitors. Key to this was the use of two 
orthogonal plasmids with tightly controlled inducible promoters for individual expression of LF 
protease and its FRET-based substrate (Figure 4). This was accomplished using the pRSF and 
pBAD families of expression vectors for the selective expression of LF and its FRET-based 
reporter, respectively. 
Based on our previous results, we decided to use an intracellular reporter with six Gly-
Gly-Ser repeats on each side of the LF recognition sequence. This long linker allows rapid 
cleavage of the LF recognition sequence while still showing a relatively high dynamic range for 
FRET change upon cleavage. This new construct (6, see Figure 1), which is virtually identical to 
5, was cloned into an expression pBAD-derived vector to give the plasmid pBAD-6. This 
expression plasmid contains an araBAD-driven promoter and a p15 replicon. LF was cloned into 
a pRSF-based vector to give the expression plasmid pRSF-LF described earlier. This expression 
vector contains a T7-driven promoter and an RSF origin of replication [43]. These two 
expression plasmids are fully compatible for the sequential expression of proteins in E. coli cells, 
and they have been used for the study of protein–protein interactions in vivo [44].
In vivo sensing of LF activity
In order to explore the potential of construct 6 to optically sense LF activity inside living 
cells, plasmids pBAD-6 and pRSF-6 were co-transformed into E. coli BL21(DE3) cells. 
Induction of FRET reporter 6 was performed first by inducing the cells overnight with L-
arabinose. Because the cells employed in this experiment were capable of metabolizing L-
arabinose, two more aliquots of L-arabinose were added every 4 hours during the first 8 hours of 
induction. The cells were also supplemented with glucose to repress any residual expression of 
LF during this time. The presence of glucose is known to repress both araBAD and T7/lac 
promoters [45; 46], but in the presence of L-arabinose the reporter protein was expressed, albeit 
at a slower rate [44; 46]. At this point the cells were harvested and resuspended in minimal 
media M9. An aliquot of these cells was analyzed by fluorescence spectroscopy (Figure 5). The 
fluorescence spectrum revealed the presence of a strong FRET emission signal at 525 nm 
indicating the presence of reporter protein 6. The in vivo FRET value (estimated as the ratio 
between the fluorescence intensities at 525 nm and 475 nm) for construct 6, however, was 
smaller than the reported for construct 5 in vitro (3.4 versus 6.2). Intrigued by this difference, 
because reporters 5 and 6 share the same linker composition, we decided to express reporter 6
using the same conditions as before but employing E. coli cells transformed only with pBAD-6 
instead. The fluorescence analysis of the resulting cells provided a similar FRET value thus 
ruling out the presence of any prematurely expressed LF as the cause for the smaller FRET value 
observed for construct 6 in vivo. Based on these results, it is very likely that the observed 
decrease in FRET efficiency inside living cells could be due to a non-specific interaction 
between the reporter protein and some unidentified component of the cellular background. 
Next, we decided to express LF and evaluate the ability of construct 6 to sense its activity 
in vivo. The previously induced fluorescent cells resuspended in M9 were complemented with 
glycerol and the appropriate antibiotic, and then induced with IPTG at 30°C. The proteolytic 
reaction was monitored by taking small aliquots of cells at different times and measuring their 
fluorescence spectra. Within 1 hour of induction, the FRET signal decreased from a value of 3.4 
(“FRET-on” state) to 0.9 (“FRET-off” state) as shown in Figure 5. Longer induction times of up 
to 5 hours gave similar fluorescence spectra and FRET ratios, indicating the cleavage reaction 
was completed in less than 1 hour. Moreover, the FRET-off state observed in vivo was 
practically identical to the value observed in vitro, further confirming the total cleavage of the 
reporter protein in vivo.
Quantification of the YPet protein before and after LF induction indicated that the concentration 
of YPet remains constant and therefore no more reporter protein was expressed during the 
induction of LF (Figure 5B). Furthermore, the intracellular concentration of construct 6 was 
estimated to be ≈ 20 µM. At these concentration levels, the propensity of cleaved CyPet and 
YPet to heterodimerize, thus increasing the FRET signal, is minimal [24; 39]. These results 
confirm that the change in FRET signal was due only to proteolytic cleavage.
Our results show that E. coli cell strains co-transformed with pBAD-6 and pRSF-LF can 
be efficiently used for in vivo screening of libraries of compounds. Key to our approach is to 
maintain LF and its substrate under the control of two tightly regulated and inducible promoters. 
This allows for discrimination between the FRET-on state, where only the substrate is expressed, 
and the FRET-off state, where LF is expressed in the presence on the substrate (Figure 5). 
Hence, addition or expression, by the same cell, of any potential LF inhibitor during the FRET-
on state can be readily screened by measuring the FRET ratio at different times during the 
induction of LF. Potential inhibitors will inhibit the cleavage of the substrate at early times of LF 
induction. In contrast, cells containing non-inhibitors will efficiently cleave the substrate, rapidly 
reaching the FRET-off state.
Summary and conclusions
In summary, we have designed several genetically encoded FRET-based reporters 
specific for the anthrax LF protease. These reporters consist of an optimized FRET pair of 
fluorescent proteins, YPet and CyPet, which were recently described by Daugherty and co-
workers [24] for the study of molecular interactions in vivo [39]. The CyPet and YPet proteins 
were linked together by a flexible linker containing a consensus recognition site for LF protease 
[36] flanked at both its N- and C-termini by several repeats of the flexible tripeptide Gly-Gly-Ser 
[41]. In vitro evaluation of the different reporters showed that at least a minimum of two Gly-
Gly-Ser repeats are required at each side of the LF peptide recognition motif for efficient 
cleavage by LF. Interestingly, the introduction of multiple Gly-Gly-Ser repeats in the linker 
between the CyPet and YPet fluorescent proteins had a relatively minor effect on the FRET 
efficiency of the protein constructs containing the longer linkers. This interesting effect has also 
been recently reported by Merkx and coworkers [41; 42] and it has been explained by the 
extremely flexible nature of these linkers [41]. In vitro evaluation of the different FRET reporters 
showed between a 9- and 14-fold decrease in FRET signal upon cleavage with LF. 
Optimized FRET reporter 5 was used next in the design of a cell-based FRET reporter for 
LF activity. This approach employs bacterial cells as individual micro-reactors where the 
substrate and the enzyme (i.e., LF protease) are sequentially expressed. This was accomplished 
by cloning FRET reporter 6 and LF into two compatible, tightly controlled and inducible 
expression plasmids. We have shown that E. coli cells co-transformed with both plasmids can be 
induced into either the FRET-on or FRET-off states by expressing only the reporter protein or 
both sequentially, respectively. The FRET signal of living bacteria induced to express reporter 6
decreased approximately 5 times in less than 1 hour upon induction of LF expression.
This result opens the possibility for in vivo screening of genetically encoded libraries 
against LF. Recent advances in the fields of protein engineering have allowed for the first time 
the biosynthesis of circular peptides inside living cells [31]. We have recently used two natural 
disulfide-containing cyclic peptides, the cyclotides Kalata B1 and MCoTI-II, and the Bowman-
Birk sunflower trypsin inhibitor (SFTI-1) as templates for the in vivo biosynthesis of peptide 
libraries using protein splicing units [32; 47]. These types of scaffolds have a tremendous 
potential for the development of therapeutic leads based on their extraordinary stability and 
potential for grafting applications [48; 49]. We envision the combination of our cell-based 
fluorescent LF reporter with the generation of cyclic peptide-based libraries will provide a 
promising alternative approach for the high-throughput screening of large biological-based 
combinatorial libraries using FACS.
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Figure Captions
Figure 1. Genetically encoded FRET reporters used in this work. Single letter codes are used to 
represent the LF recognition sequence and flexible linker. Expected masses were calculated for 
the mature proteins without N-terminal methionine.
Figure 2. Expression and purification of FRET reporter protein 2. A. Gradient SDS-PAGE 
analysis of bacterial cell lysate expressing reporter 2 (line 1) and after purification by Ni-NTA 
affinity chromatography (line 2). B. ES-MS analysis of purified FRET reporter 2.
Figure 3. In vitro cleavage of FRET reporter 1 to 5 by LF protease. A. Fluorescence spectra of a 
10 nM solution of construct 3 incubated with LF (100 nM) at different time points. Excitation 
was done at 413 nm. B. Analysis of the proteolytic cleavage of construct 3 by gradient SDS-
PAGE. C. Effect of the Gly-Gly-Ser linker length on the cleavage rate by LF. D. Fluorescence 
analysis of a 10 nM solution of construct 3 cleaved with different concentrations of LF protease. 
The FRET ratio change was calculated as described under Materials and Methods.
Figure 4. Scheme employed for the production of a cell-based reporter for screening LF activity 
inside living bacterial cells.
Figure 5. A. In vivo cleavage of FRET reporter 6 followed by fluorescence spectroscopy. A. 
Fluorescence spectra of E. coli cells expressing reporter 6 in the presence (green line) or absence 
(red line) of LF. B. Quantification of fluorescent protein YPet was performed on live E. coli cells 
expressing reporter 6 in the presence (green line) or absence (red line) of LF. Cells were excited 
at 490 nm. 
Table 1. Oligonucleotides used to encode different LF recognition sites containing a variable 
number of (Gly-Gly-Ser)n repeats.
Construct 1
p5: 5’-GAT CCC  GTC GTA AAA AAG TTT ATC CGT ATC CGA TGG AAG GTA CCA TCG CCC A-3’
p3: 5’-AGC TTG GGC GAT GGT ACC TTC CAT CGG ATA CGG ATA AAC TTT TTT ACG ACG G-3’
Construct 2
p5: 5’-GAT CCG GTG GCA GCC GTC GTA AAA AAG TTT ATC CGT ATC CGA TGG AAC CGA CCA 
TCG CCG  GTG GCA  GCC A-3’
p3: 5’-AGC TTG GCT GCC ACC GGC GAT GGT CGG TTC CAT CGG ATA CGG ATA AAC TTT TTT ACG 
ACG GCT GCC ACC G-3’
Construct: 3
p5: 5’- GAT CCG GTG GCA GCG GTG GCA GCC GTC GTA AAA AAG TTT ATC CGT ATC CGA TGG 
AAC CGA CCA TCG CCG GTG GCA GCG GTG GCA GCC A-3’
p3: 5’- AGC TTG GCT GCC ACC GCT GCC ACC GGC GAT GGT CGG TTC CAT CGG ATA CGG ATA 
AAC TTT TTT ACG ACG GCT GCC ACC GCT GCC ACC G-3’
Construct: 4
p5a: 5’-GAT CCG GTG GCA GCG GTG GCA GCG GTG GCA GCG GTG GCA GCC GTC GTA AAA AAG 
TTT ATC C-3’
p3a: :  5’-GAT ACG GAT AAA CTT TTT TAC GAC GGC TGC CAC CGC TGC CAC CGC TGC CAC CGC 
TGC CAC CG-3’
p5b: 5’- GTA TCC GAT GGA ACC GAC CAT CGC CGG TGG CAG CGG TGG CAG CGG TGG CAG CGG 
TGG CAG CCA-3’
p3b: 5’- AGC TTG GCT GCC ACC GCT GCC ACC GCT GCC ACC GCT GCC ACC GGC GAT GGT CGG 
TTC CAT CG-3’
Construct: 5
p5a: 5’- GAT CCG GTG GCA GCG GTG GCA GCG GTG GCA GCG GTG GCA GCG GTG GCA GCG GTG 
GCA GCC GTC GTA AAA AAG TTT ATC C-3’
p3a: 5’- GAT ACG GAT AAA CTT TTT TAC GAC GGC TGC CAC CGC TGC CAC CGC TGC CAC CGC 
TGC CAC CGC TGC CAC CGC TGC CAC CG-3’
p5b: 5’- GTA TCC GAT GGA ACC GAC CAT CGC CGG TGG CAG CGG TGG CAG CGG TGG CAG CGG 
TGG CAG CGG TGG CAG CGG TGG CAG CCA-3’
p3b: 5’- AGC TTG GCT GCC ACC GCT GCC ACC GCT GCC ACC GCT GCC ACC GCT GCC ACC GCT 
GCC ACC GGC GAT GGT CGG TTC CAT CG-3’
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